Immunocore (IMCR)

• Market cap: $1.48B
• 1 day: 4.51%
• 5 days: 4.29%
• 1 month: 8.97%
• 3 months: 4.01%
• 6 months: -2.19%
• Year to date: 1.84%
• 1 year: -44.02%
• 5 years: -29.70%
• 10 years: -29.70%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Employees: 493

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

88% more call options, than puts

Call options by funds: $6.54M | Put options by funds: $3.48M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

3.64% more ownership

Funds ownership: 90.74% [Q4 2024] → 94.38% (+3.64%) [Q1 2025]

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

5% more capital invested

Capital invested by funds: $1.34B [Q4 2024] → $1.4B (+$62.8M) [Q1 2025]

0% more funds holding

Funds holding: 113 [Q4 2024] → 113 (+0) [Q1 2025]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $33 9% upside
• Avg. target: $63 106% upside
• High target: $100 229% upside

6 analyst ratings

• positive: 4 67%
• neutral: 2 33%
• negative: 0 0%

Oppenheimer Jeff Jones 9% 1-year accuracy 3 / 33 met price target	183% upside $86	Outperform Maintained	8 May 2025
JP Morgan Jessica Fye 44% 1-year accuracy 18 / 41 met price target	65% upside $50	Overweight Maintained	14 Apr 2025
Needham Gil Blum 21% 1-year accuracy 31 / 147 met price target	134% upside $71	Buy Reiterated	10 Apr 2025
Mizuho Graig Suvannavejh 26% 1-year accuracy 5 / 19 met price target	9% upside $33	Neutral Maintained	7 Apr 2025
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 39 / 170 met price target	229% upside $100	Buy Reiterated	12 Mar 2025